General Information of Drug (ID: DMY3J0B)

Drug Name
(+/-)-cis-2-CAMP Drug Info
Synonyms
215597-45-8; 2-(Aminomethyl)cyclopropanecarboxylic acid; 2-(aminomethyl)cyclopropane-1-carboxylic acid; Cyclopropanecarboxylicacid, 2-(aminomethyl)-; (plusmn)-cis-2-CAMP; AC1N3MNT; SCHEMBL3943045; GTPL4067; CHEMBL284310; CTK1A0098; BDBM50087269; AKOS006277884; KB-163238; (cis)-2-Aminomethyl-cyclopropanecarboxylic acid; A29700; (trans)-2-Aminomethyl-cyclopropanecarboxylic acid; (+)-2-(aminomethyl)-cyclopropane-1-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
4067175
TTD Drug ID
DMY3J0B

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TBPS DMFC3XP Discovery agent N.A. Investigative [4]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [4]
piperidine-4-sulphonic acid DMMIZWE Discovery agent N.A. Investigative [4]
trans-3-ACPBPA DM6HI8W Discovery agent N.A. Investigative [4]
cis-3-ACPBPA DMQ0EA7 Discovery agent N.A. Investigative [4]
5-Me-IAA DMFZN7J Discovery agent N.A. Investigative [4]
aza-THIP DML70NC Discovery agent N.A. Investigative [4]
TPMPA DMBF6KS Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TBPS DMFC3XP Discovery agent N.A. Investigative [3]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [3]
piperidine-4-sulphonic acid DMMIZWE Discovery agent N.A. Investigative [3]
trans-3-ACPBPA DM6HI8W Discovery agent N.A. Investigative [3]
cis-3-ACPBPA DMQ0EA7 Discovery agent N.A. Investigative [3]
5-Me-IAA DMFZN7J Discovery agent N.A. Investigative [3]
aza-THIP DML70NC Discovery agent N.A. Investigative [3]
TPMPA DMBF6KS Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TBPS DMFC3XP Discovery agent N.A. Investigative [2]
isonipecotic acid DMO1ZHE Discovery agent N.A. Investigative [2]
piperidine-4-sulphonic acid DMMIZWE Discovery agent N.A. Investigative [2]
trans-3-ACPBPA DM6HI8W Discovery agent N.A. Investigative [2]
cis-3-ACPBPA DMQ0EA7 Discovery agent N.A. Investigative [2]
5-Me-IAA DMFZN7J Discovery agent N.A. Investigative [2]
aza-THIP DML70NC Discovery agent N.A. Investigative [2]
TPMPA DMBF6KS Discovery agent N.A. Investigative [2]
CACA DMPKFYZ Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor rho1 (GABRR1) TT6XFEU GBRR1_HUMAN Agonist [2]
GABA(A) receptor rho2 (GABRR2) TTQMXLS GBRR2_HUMAN Agonist [3]
GABA(A) receptor rho3 (GABRR3) TT4N6D8 GBRR3_HUMAN Agonist [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4067).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422).
5 Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in Xenopus oocytes. II. Pharmacology of gamma-aminobutyric acidA and gamma-aminobutyric acidB receptor agonists and antagonists. Mol Pharmacol. 1993 Apr;43(4):609-25.